Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Exclusive ex-China license for civorebrutinib, expanding Travere’s pipeline into a potential multi-indication BTK opportunity.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive ex-China license for civorebrutinib, expanding Travere’s pipeline into a potential multi-indication BTK opportunity
- $112.5M upfront payment, plus approximately $1.03B in development, regulatory and commercial milestones
- Tiered royalties from high single-digit to double-digit percentages on Territory net sales, creating future margin obligations
- Shared global-trial costs, with Travere responsible for Territory development and commercialization
- Ten-year prohibition on competing BTK products increases strategic commitment and execution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.